Drug intelligence / Profile preview

SYS6016

Development stage
Phase 1
Lead developer
Suzhou Xinnuowei Pharmaceutical Technology
Modality
Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration
Intramuscular
01

Overview

SYS6016 is an mRNA-based vaccine developed by CSPC Megalith Biopharmaceutical, a subsidiary of CSPC Pharmaceutical Group, for the prevention of lower respiratory tract diseases caused by Respiratory Syncytial Virus (RSV). The vaccine utilizes synthetic messenger RNA technology formulated in lipid nanoparticles (LNP) to target both RSV-A and RSV-B subtypes. By inducing the production of viral antigens, it triggers a protective antibody response. In July 2024, the Chinese National Medical Products Administration (NMPA) granted clinical trial approval for SYS6016 to enter Phase 1 human trials, following preclinical studies that demonstrated a favorable safety profile and long-lasting immunogenicity.

Other names
SYS6016SYS-6016SYS 6016
02

Targets

RSV F (Respiratory syncytial virus fusion protein)

Beyond the preview

Go deeper on SYS6016.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on SYS6016.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call